300254 仟源医药
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入611,4730.44%846,606799,305828,997930,375
减:营业总成本552,167-1.96%792,256803,213894,7461,003,390
    其中:营业成本197,366-1.80%280,157257,473250,893282,203
               财务费用17,52350.80%15,79429,54043,02047,266
               资产减值损失1,247-164.05%(7,319)(6,550)(48,516)(39,395)
公允价值变动收益------------
投资收益1,469-61.95%4,54420,882(3,431)13,638
    其中:对联营企业和合营企业的投资收益1,300-4,530.31%1,01020,882(3,431)8,090
营业利润70,85414.83%64,99440,154(115,093)(79,572)
利润总额77,3695.40%80,64355,279(90,020)(65,478)
减:所得税费用28,899362.46%5,8836,5537,8999,068
净利润48,471-27.83%74,76048,726(97,919)(74,546)
减:非控股权益26,14313.64%32,56923,53120,60216,892
股东净利润22,327-49.43%42,19025,196(118,520)(91,438)

市场价值指针
每股收益 (元) *0.092-49.53%0.1750.104-0.500-0.401
每股派息 (元) *------------
每股净资产 (元) *1.148-55.98%1.3812.4842.3792.585
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容